Five year survival is up to 65 % among operated patients with early discovery of non-small cell lung cancer, while long-term survival is 1% in those with metastasis.
Without surgical intervention, the prognosis is not significantly different for small cell and non-small cell lung carcinoma.
For small cell lung cancer, the long term survival in limited stage disease is 15 % and 0–1 % in extensive stage disease (28).
In Norway, during the period 2007-2011, five year relative survival for all stages was 12,1 % in men and 16,8 % in women.
For localized cancer (Stage I, II), the prognosis is better. During the period 2007-2011, five year survival for men was 40.2 % and 50.5 % for women.
Five-year relative survival for patients with lung cancer, in percent, during the diagnosis period 1974–2013.
Source: Cancer Registry of Norway
For the prognosis of lung cancer, prognostic factors and the stage of the cancer at the time of diagnosis are more significant than the kind of treatment given.
Poor prognostic factors
- WHO/ECOG status ≥ 2
- Greatest tumor diameter ≥ 9 cm
- Weight loss > 5–10% in the last 3 months
Good prognostic factors
- WHO/ECOG status < 2
- Greatest tumor diameter < 9 cm
- Weight loss < 5–10% in the last 3 months
WHO performance status
- 0: Asymptomatic (Fully active, able to carry on all predisease activities without restriction.)
- 1: Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)
- 2: Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours)
- 3: Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours)
- 4: Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair)
- 5: Death